-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $90

Benzinga·08/06/2026 13:51:35
Listen to the news
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $100 to $90.